NovaBridge Biosciences (NBP) NASDAQ
2.60
+0.06(+2.36%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
2.60
+0.06(+2.36%)
Currency In USD
Address
2440 Research Boulevard
Rockville, MD 20850
United States of America (the)
Phone
240 745 6330
Sector
Healthcare
Industry
Biotechnology
Employees
32
First IPO Date
January 17, 2020
| Name | Title | Pay | Year Born |
| Xi-Yong Fu | Chief Executive Officer & Director | 0 | 1972 |
| Claire Xu | Senior Vice President of Clinical Development | 0 | N/A |
| Phillip Dennis | Chief Medical Officer | 0 | 1963 |
| Kyler Lei | Chief Financial Officer | 0 | N/A |
| Sean Wuxiong Cao | Chief Business Development Officer & Independent Director | 0 | N/A |
| Tyler Ehler | Senior Director of Investor Relations | 0 | N/A |
| Wei Fu | Executive Chairman | 0 | 1982 |
NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.